Ginkgo Bioworks Holdings, Inc.
Data quality: 100%
$7.79
▲
$0.07
(0.91%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-14.19%
Growth
Revenue Growth (5Y)
-14.19%
Below sector avg (1.82%)
Revenue (1Y)-25.06%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-53.34%
Above sector avg (-54.68%)
ROIC-22.56%
Net Margin-183.81%
Op. Margin-185.29%
Safety
Debt / Equity
N/A
Current Ratio4.39
Interest CoverageN/A
Valuation
PE (TTM)
-1.26
Above sector avg (-1.49)
P/B Ratio0.71
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -14.19% annually over 5 years
Negative free cash flow of -178.72 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 10.87%
Capital efficient — spends only 4.50% of revenue on capex
Price History
Financial Trends
Analyst Price Target
3 analysts
Sell
+11.3%
upside to target
Current
$7.79
Consensus Target
$8.67
$5.00
Low
$12.00
High
Forecast
Forward EPS
-$3.86
Est. Revenue
158.63 M
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$1.34
·
Rev Est: 42.96 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$1.68 | -$1.10 | -$1.45 | -$0.77 | — | — |
| Estimate | -$1.77 | -$1.57 | -$1.24 | -$1.11 | -$1.34 | -$1.32 |
| Surprise | +5.08% | +29.79% | -16.94% | +30.50% | — | — |
Growth
Rev 5Y: -14.19% · Earnings 1Y: N/A
Growth
Rev 5Y: -14.19% · Earnings 1Y: N/A| Revenue Growth (1Y) | -25.06% | Revenue Growth (3Y) | -17.74% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -14.19% | Earnings Growth (5Y) | N/A |
Profitability
ROE: -53.34% · Net Margin: -183.81%
Profitability
ROE: -53.34% · Net Margin: -183.81%| Revenue (TTM) | 170.16 M | Net Income (TTM) | -312.76 M |
| ROE | -53.34% | ROA | -25.85% |
| Gross Margin | N/A | Operating Margin | -185.29% |
| Net Margin | -183.81% | Free Cash Flow (TTM) | -178.72 M |
| ROIC | -22.56% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 4.39
Safety
D/E: N/A · Current: 4.39| Debt / Equity | N/A | Current Ratio | 4.39 |
| Interest Coverage | N/A | Asset Turnover | 0.14 |
| Working Capital | 390.80 M | Tangible Book Value | 498.26 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -1.26 · EV/EBITDA: N/A
Valuation
P/E: -1.26 · EV/EBITDA: N/A| P/E Ratio | -1.26 | Forward P/E | N/A |
| P/B Ratio | 0.71 | P/S Ratio | 2.32 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 2.49 | Fwd Earnings Yield | N/A |
| FCF Yield | -45.27% | ||
| Market Cap | 394.77 M | Enterprise Value | 283.70 M |
Per Share
EPS: -5.64 · FCF/Share: -2.89
Per Share
EPS: -5.64 · FCF/Share: -2.89| EPS (Diluted TTM) | -5.64 | Revenue / Share | 2.75 |
| FCF / Share | -2.89 | OCF / Share | -2.76 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 57.14% · CapEx/Rev: 4.50%
Efficiency
FCF Conv: 57.14% · CapEx/Rev: 4.50%| CapEx / Revenue | 4.50% | FCF Conversion | 57.14% |
| SBC-Adj. FCF | -253.10 M | Growth Momentum | -10.87 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 170.16 M | 227.04 M | 251.46 M | 477.71 M | 313.84 M |
| Net Income | -312.76 M | -547.03 M | -892.87 M | -2.10 B | -1.83 B |
| EPS (Diluted) | -5.64 | -10.54 | -0.46 | -1.25 | -1.39 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -315.28 M | -559.76 M | -864.41 M | -2.21 B | -1.83 B |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 243.77 M | 424.06 M | 580.62 M | 1.05 B | 1.15 B |
| SG&A Expenses | — | — | — | — | — |
| D&A | 58.99 M | 63.02 M | 70.51 M | 42.55 M | 29.08 M |
| Interest Expense | 0.0 | 94,000.0 | 93,000.0 | 106,000.0 | 2.37 M |
| Income Tax | -837,000.0 | -479,000.0 | -71,000.0 | -15.03 M | -1.48 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.12 B | 1.38 B | 1.67 B | 2.54 B | 2.07 B |
| Total Liabilities | 611.11 M | 661.39 M | 568.19 M | 803.04 M | 503.61 M |
| Shareholders' Equity | 508.59 M | 716.06 M | 1.10 B | 1.74 B | 1.51 B |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 167.20 M | 561.57 M | 944.07 M | 1.32 B | 1.55 B |
| Current Assets | 471.84 M | 602.74 M | 1.00 B | 1.45 B | 1.72 B |
| Current Liabilities | 95.97 M | 107.27 M | 163.86 M | 172.96 M | 134.76 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.3 | -1.5 |
| P/B | 0.7 | 1.6 |
| ROE % | -53.3 | -54.7 |
| Net Margin % | -183.8 | -41.5 |
| Rev Growth 5Y % | -14.2 | 1.8 |
| D/E | — | 0.3 |
ETFs Holding This Stock
ETFs Holding This Stock
{"event":"ticker_viewed","properties":{"ticker":"DNA","listing_kind":"stock","pathname":"/stocks/dna","exchange":"NYSE","country":"US"}}